◆ Market Terminal AILook up a stock

Gilead Sciences, Inc. (GILD)

Healthcare · Drug Manufacturers - General · Large-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Gilead Sciences, Inc. is a weaker business by our measures, its shares look fairly priced, and its share price has been doing well.
Value58
Quality31
Price trend85
Overall55
827 of 2764rank among the US stocks we score (our core model buys the top 15)
70%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$29.4B
Sales growthchange from the year before+2.4%
Gross marginshare of sales left after the direct cost of what it sells78.8%
Operating marginshare of sales left after running the business34.0%
Net marginshare of sales kept as profit28.9%
Free-cash-flow marginspare cash generated per $100 of sales32.1%
Return on invested capitalprofit made on each $100 put into the business16.6%
Return on equityprofit vs. shareholders' accounting value37.5%
Debt / equitydebt vs. shareholders' accounting value1.10
Change in share countnegative = the company is buying back its shares0.0%

Insider trades, last 90 days

1 insider sold $2.0M (all under pre-arranged plans) on the open market.

O'Day Daniel PatrickChairman & CEO · DirectorSold (plan)Aug 315,000 shat $130.31 · $2.0M

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy